Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)

Clinical trial NCT04423731 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04423731
Sponsor: Oslo University Hospital
Status: ACTIVE_NOT_RECRUITING
Study type: OBSERVATIONAL

Locally Advanced Pancreatic Adenocarcinoma Chemotherapy Effect Borderline Resectable Pancreatic Adenocarcinoma Pancreatectomy

Start date: 2018-01-01
Primary completion: 2022-10-31
Enrollment: 251

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.